Attention Canadian patients who have inflammatory bowel disease (IBD): Crohn’s disease and ulcerative colitis.


Janssen Canada has engaged a third party to conduct a survey to learn about your opinions and experiences regarding therapies for IBD. They will use the data in aggregate and Janssen will not receive any of your personal information. If you include your contact information after completing the survey, your name will go into a draw by the third party for an iPad.

Janssen is working with a national steering committee of gastroenterologists in the design and analysis of this survey, to help us understand the opinions and outlooks of patients regarding the benefit and safety profile of medications used for the treatment of IBD. When guiding patients through treatment options, physicians might share certain product features that they believe are most important. However, patients might place more importance on different product features. We want to learn what patients really want from a treatment.

The Gastrointestinal Society will report on the results in an upcoming issue of the Inside Tract® newsletter.